Does the media prefer VTRS or DFTX?

In the previous week, Definium Therapeutics had 7 more articles in the media than Viatris. MarketBeat recorded 8 mentions for Definium Therapeutics and 1 mentions for Viatris. Definium Therapeutics' average media sentiment score of 0.62 beat Viatris' score of 0.50 indicating that Definium Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Definium Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer JAZZ or DFTX?

In the previous week, Definium Therapeutics had 5 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 8 mentions for Definium Therapeutics and 3 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.71 beat Definium Therapeutics' score of 0.62 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Definium Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DFTX or NBIX?

In the previous week, Neurocrine Biosciences had 12 more articles in the media than Definium Therapeutics. MarketBeat recorded 20 mentions for Neurocrine Biosciences and 8 mentions for Definium Therapeutics. Neurocrine Biosciences' average media sentiment score of 1.43 beat Definium Therapeutics' score of 0.62 indicating that Neurocrine Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 19 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CORT or DFTX?

In the previous week, Corcept Therapeutics had 25 more articles in the media than Definium Therapeutics. MarketBeat recorded 33 mentions for Corcept Therapeutics and 8 mentions for Definium Therapeutics. Corcept Therapeutics' average media sentiment score of 0.83 beat Definium Therapeutics' score of 0.62 indicating that Corcept Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 14 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Definium Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DFTX or ELAN?

In the previous week, Elanco Animal Health had 8 more articles in the media than Definium Therapeutics. MarketBeat recorded 16 mentions for Elanco Animal Health and 8 mentions for Definium Therapeutics. Elanco Animal Health's average media sentiment score of 1.59 beat Definium Therapeutics' score of 0.62 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Definium Therapeutics (DFTX) Competitors

$43.27 -1.64 (-3.65%)

As of 04:00 PM Eastern

Compare

DFTX vs. VTRS, JAZZ, NBIX, CORT, and ELAN

Should you buy Definium Therapeutics stock or one of its competitors? Definium Therapeutics's main competitors and comparable companies include Viatris (VTRS), Jazz Pharmaceuticals (JAZZ), Neurocrine Biosciences (NBIX), Corcept Therapeutics (CORT), and Elanco Animal Health (ELAN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Definium Therapeutics compare to Viatris?

Viatris (NASDAQ:VTRS) and Definium Therapeutics (NASDAQ:DFTX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

Viatris has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.23, indicating that its stock price is 123% more volatile than the broader market.

Definium Therapeutics has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.33	-$3.51B	-$0.36	N/A
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A

In the previous week, Definium Therapeutics had 7 more articles in the media than Viatris. MarketBeat recorded 8 mentions for Definium Therapeutics and 1 mentions for Viatris. Definium Therapeutics' average media sentiment score of 0.62 beat Viatris' score of 0.50 indicating that Definium Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Definium Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Definium Therapeutics has a net margin of 0.00% compared to Viatris' net margin of -2.79%. Viatris' return on equity of 20.02% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.79%	20.02%	8.02%
Definium Therapeutics	N/A	-84.01%	-63.66%

79.9% of Viatris shares are held by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are held by institutional investors. 0.3% of Viatris shares are held by insiders. Comparatively, 2.4% of Definium Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Viatris presently has a consensus price target of $17.50, indicating a potential upside of 5.80%. Definium Therapeutics has a consensus price target of $63.00, indicating a potential upside of 45.60%. Given Definium Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Definium Therapeutics is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Definium Therapeutics beats Viatris on 11 of the 16 factors compared between the two stocks.

How does Definium Therapeutics compare to Jazz Pharmaceuticals?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Definium Therapeutics (NASDAQ:DFTX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

In the previous week, Definium Therapeutics had 5 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 8 mentions for Definium Therapeutics and 3 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.71 beat Definium Therapeutics' score of 0.62 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Definium Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are owned by institutional investors. 4.1% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 2.4% of Definium Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Jazz Pharmaceuticals has a net margin of 20.45% compared to Definium Therapeutics' net margin of 0.00%. Jazz Pharmaceuticals' return on equity of 33.97% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	20.45%	33.97%	13.02%
Definium Therapeutics	N/A	-84.01%	-63.66%

Definium Therapeutics has lower revenue, but higher earnings than Jazz Pharmaceuticals. Definium Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.87	-$356.15M	$14.50	17.55
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A

Jazz Pharmaceuticals presently has a consensus price target of $272.89, suggesting a potential upside of 7.24%. Definium Therapeutics has a consensus price target of $63.00, suggesting a potential upside of 45.60%. Given Definium Therapeutics' higher possible upside, analysts clearly believe Definium Therapeutics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	3.00
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00

Jazz Pharmaceuticals has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market.

Summary

Jazz Pharmaceuticals beats Definium Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Definium Therapeutics compare to Neurocrine Biosciences?

Definium Therapeutics (NASDAQ:DFTX) and Neurocrine Biosciences (NASDAQ:NBIX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

Definium Therapeutics presently has a consensus target price of $63.00, indicating a potential upside of 45.60%. Neurocrine Biosciences has a consensus target price of $200.86, indicating a potential upside of 31.25%. Given Definium Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Definium Therapeutics is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88

27.9% of Definium Therapeutics shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 2.4% of Definium Therapeutics shares are owned by insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Neurocrine Biosciences had 12 more articles in the media than Definium Therapeutics. MarketBeat recorded 20 mentions for Neurocrine Biosciences and 8 mentions for Definium Therapeutics. Neurocrine Biosciences' average media sentiment score of 1.43 beat Definium Therapeutics' score of 0.62 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurocrine Biosciences	19 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurocrine Biosciences has a net margin of 20.91% compared to Definium Therapeutics' net margin of 0.00%. Neurocrine Biosciences' return on equity of 22.43% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Neurocrine Biosciences	20.91%	22.43%	15.64%

Definium Therapeutics has a beta of 2.23, indicating that its share price is 123% more volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market.

Neurocrine Biosciences has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Neurocrine Biosciences	$2.86B	5.44	$478.60M	$6.82	22.44

Summary

Neurocrine Biosciences beats Definium Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Definium Therapeutics compare to Corcept Therapeutics?

Corcept Therapeutics (NASDAQ:CORT) and Definium Therapeutics (NASDAQ:DFTX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are owned by institutional investors. 20.7% of Corcept Therapeutics shares are owned by insiders. Comparatively, 2.4% of Definium Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Corcept Therapeutics has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41M	17.50	$99.65M	$0.42	293.43
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A

Corcept Therapeutics currently has a consensus target price of $138.17, indicating a potential upside of 12.11%. Definium Therapeutics has a consensus target price of $63.00, indicating a potential upside of 45.60%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Definium Therapeutics is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Corcept Therapeutics had 25 more articles in the media than Definium Therapeutics. MarketBeat recorded 33 mentions for Corcept Therapeutics and 8 mentions for Definium Therapeutics. Corcept Therapeutics' average media sentiment score of 0.83 beat Definium Therapeutics' score of 0.62 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	14 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Definium Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Corcept Therapeutics has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the broader market.

Corcept Therapeutics has a net margin of 6.52% compared to Definium Therapeutics' net margin of 0.00%. Corcept Therapeutics' return on equity of 8.26% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.52%	8.26%	6.45%
Definium Therapeutics	N/A	-84.01%	-63.66%

Summary

Corcept Therapeutics beats Definium Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Definium Therapeutics compare to Elanco Animal Health?

Definium Therapeutics (NASDAQ:DFTX) and Elanco Animal Health (NYSE:ELAN) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

Definium Therapeutics currently has a consensus price target of $63.00, suggesting a potential upside of 45.60%. Elanco Animal Health has a consensus price target of $29.09, suggesting a potential upside of 19.18%. Given Definium Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Definium Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Definium Therapeutics has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Elanco Animal Health	$4.72B	2.59	-$232M	-$0.41	N/A

In the previous week, Elanco Animal Health had 8 more articles in the media than Definium Therapeutics. MarketBeat recorded 16 mentions for Elanco Animal Health and 8 mentions for Definium Therapeutics. Elanco Animal Health's average media sentiment score of 1.59 beat Definium Therapeutics' score of 0.62 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

27.9% of Definium Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 2.4% of Definium Therapeutics shares are held by insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Definium Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -3.96%. Elanco Animal Health's return on equity of 8.13% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Elanco Animal Health	-3.96%	8.13%	3.99%

Definium Therapeutics has a beta of 2.23, indicating that its share price is 123% more volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market.

Summary

Definium Therapeutics beats Elanco Animal Health on 9 of the 16 factors compared between the two stocks.

Get Definium Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DFTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DFTX vs. The Competition

Export

Metric	Definium Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.03B	$12.53B	$7.36B	$12.81B
Dividend Yield	N/A	2.61%	2.53%	10.78%
P/E Ratio	-12.62	780.42	270.55	24.05
Price / Sales	N/A	754.07	630.76	95.90
Price / Cash	N/A	15.47	29.03	36.89
Price / Book	12.88	10.42	11.18	6.40
Net Income	-$183.79M	$2.79B	$3.46B	$347.95M
7 Day Performance	-4.40%	2.25%	1.98%	0.91%
1 Month Performance	0.23%	4.72%	7.32%	5.10%
1 Year Performance	324.63%	7.07%	24.76%	16.16%

Definium Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DFTX Definium Therapeutics	3.0961 of 5 stars	$43.27 -3.7%	$63.00 +45.6%	+340.7%	$6.03B	N/A	N/A	40
VTRS Viatris	1.842 of 5 stars	$16.23 flat	$17.50 +7.8%	+53.2%	$18.64B	$14.30B	N/A	30,000	Positive News Ex-Dividend
JAZZ Jazz Pharmaceuticals	4.0912 of 5 stars	$248.36 +1.4%	$272.89 +9.9%	+106.5%	$15.90B	$4.27B	17.13	2,890	Positive News
NBIX Neurocrine Biosciences	4.9823 of 5 stars	$154.49 +1.2%	$200.86 +30.0%	+12.7%	$15.52B	$2.86B	22.65	2,000	Positive News
CORT Corcept Therapeutics	3.405 of 5 stars	$117.17 +2.4%	$119.17 +1.7%	+73.8%	$12.37B	$761.41M	278.98	300	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DFTX) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Definium Therapeutics (DFTX) Competitors

DFTX vs. VTRS, JAZZ, NBIX, CORT, and ELAN

How does Definium Therapeutics compare to Viatris?

Summary

How does Definium Therapeutics compare to Jazz Pharmaceuticals?

Summary

How does Definium Therapeutics compare to Neurocrine Biosciences?

Summary

How does Definium Therapeutics compare to Corcept Therapeutics?

Summary

How does Definium Therapeutics compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DFTX vs. The Competition

Definium Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Definium Therapeutics (DFTX) Competitors

DFTX vs. VTRS, JAZZ, NBIX, CORT, and ELAN

How does Definium Therapeutics compare to Viatris?

Which has more risk & volatility, VTRS or DFTX?

Which has stronger earnings & valuation, VTRS or DFTX?

Does the media prefer VTRS or DFTX?

Is VTRS or DFTX more profitable?

Do institutionals & insiders have more ownership in VTRS or DFTX?

Do analysts recommend VTRS or DFTX?

Summary

How does Definium Therapeutics compare to Jazz Pharmaceuticals?

Does the media prefer JAZZ or DFTX?

Do institutionals and insiders hold more shares of JAZZ or DFTX?

Is JAZZ or DFTX more profitable?

Which has better valuation & earnings, JAZZ or DFTX?

Do analysts rate JAZZ or DFTX?

Which has more volatility & risk, JAZZ or DFTX?

Summary

How does Definium Therapeutics compare to Neurocrine Biosciences?

Do analysts rate DFTX or NBIX?

Do institutionals & insiders have more ownership in DFTX or NBIX?

Does the media refer more to DFTX or NBIX?

Is DFTX or NBIX more profitable?

Which has more risk and volatility, DFTX or NBIX?

Which has stronger earnings and valuation, DFTX or NBIX?

Summary

How does Definium Therapeutics compare to Corcept Therapeutics?

Do institutionals and insiders believe in CORT or DFTX?

Which has preferable earnings & valuation, CORT or DFTX?

Do analysts prefer CORT or DFTX?

Does the media prefer CORT or DFTX?

Which has more risk and volatility, CORT or DFTX?

Is CORT or DFTX more profitable?

Summary

How does Definium Therapeutics compare to Elanco Animal Health?

Do analysts recommend DFTX or ELAN?

Which has preferable valuation & earnings, DFTX or ELAN?

Does the media refer more to DFTX or ELAN?

Do insiders & institutionals have more ownership in DFTX or ELAN?

Is DFTX or ELAN more profitable?

Which has more risk and volatility, DFTX or ELAN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DFTX vs. The Competition

Definium Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools